文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗特应性皮炎的长期有效性及停药原因

Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.
PubMed 文献 · JAMA Dermatol · 2024-01-01

这项前瞻性多中心队列研究基于荷兰BioDay注册库,纳入2017年10月至2022年12月接受度普利尤单抗治疗的特应性皮炎患者1286例(儿童130例、成人1025例、老年人131例),随访最长5年。结果显示多数患者病情维持控制,EASI≤7者占78.6%–92.3%,瘙痒NRS≤4者占72.2%–88.2%;23.8%患者停药,最常见原因为不良事件(7.6%)和疗效不佳(6.6%)。

要点

  • 度普利尤单抗治疗5年内多数特应性皮炎患者维持疾病控制。
  • 高达70.5%患者将给药间隔延长至每3或4周一次。
  • 23.8%患者停药,主要因不良事件或疗效不佳。

核心结论

  • 度普利尤单抗在长达5年随访中维持临床有效性,但23.8%患者停药,主要原因为不良事件和疗效不佳。
  • 约三分之二患者将给药间隔延长至每3或4周一次。

研究设计与样本

  • 前瞻性多中心队列研究,使用荷兰BioDay注册库(4家学术医院和10家非学术医院)。
  • 纳入2017年10月至2022年12月接受度普利尤单抗治疗的特应性皮炎患者1286例,中位年龄38岁(IQR 26–54),男性726例(56.6%)。
  • 按年龄分层:儿童(<18岁)130例、成人(18–64岁)1025例、老年人(≥65岁)131例;中位随访87.5周(IQR 32.0–157.0)。

主要发现

  • 治疗5年内EASI≤7的患者比例在78.6%至92.3%之间,瘙痒NRS≤4的患者比例在72.2%至88.2%之间。
  • 治疗5年后平均EASI为2.7(95%CI 1.2–4.2),平均瘙痒NRS为3.5(95%CI 2.7–4.3)。
  • 年龄组间EASI和IGA随时间变化差异有统计学意义但幅度较小(第52周:EASI差异0.3–1.6;IGA差异0.12–0.26),瘙痒NRS无统计学显著差异。
  • 中位胸腺和活化调节趋化因子水平从1751 pg/mL(95%CI 1614–1900 pg/mL)降至治疗6个月后的390 pg/mL(95%CI 368–413 pg/mL)并维持低水平;中位嗜酸性粒细胞水平至第16周暂时升高,随后随时间显著下降。
  • 306例(23.8%)停药,中位停药时间54.0周(IQR 29.0–110.0),最常见原因为不良事件(98例,7.6%)和疗效不佳(85例,6.6%);41例(3.2%)重启度普利尤单抗,多数重新获得应答。

关键数值与推荐

  • 疾病控制定义为EASI≤7且瘙痒NRS≤4。
  • 延长给药间隔者高达70.5%,多数为300 mg每3或4周一次。

临床怎么用

  • 度普利尤单抗长期治疗可维持特应性皮炎疾病控制,临床可考虑对应答良好者延长给药间隔至每3或4周一次。
  • 需监测不良事件和疗效不佳,二者是停药的主要原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice. OBJECTIVE: To evaluate clinical effectiveness and reasons for discontinuation of dupilumab treatment in children, adults, and older adults with AD with up to 5 years of treatment in daily practice. DESIGN, SETTING, AND PARTICIPANTS: This prospective multicenter cohort study was conducted using the BioDay registry (4 academic and 10 nonacademic hospitals in the Netherlands) to identify patients with AD of all ages who were treated with dupilumab between October 2017 and December 2022. MAIN OUTCOMES AND MEASURES: Clinical effectiveness was evaluated by the Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), and numeric rating scale (NRS) for pruritus, stratified by children (<18 years), adults (18-64 years), and older adults (≥65 years). In addition, time to response, treatment responders, EASI subscores, second treatment episodes, and thymus- and activation-related chemokine and eosinophil levels were assessed. For patients who discontinued dupilumab, the reason for discontinuation was evaluated. RESULTS: In total, 1286 patients with AD (median [IQR] age, 38 [26-54] years; 726 [56.6%] male) were treated with dupilumab, including 130 children, 1025 adults, and 131 older adults. The median (IQR) follow-up time was 87.5 (32.0-157.0) weeks. Most patients maintained controlled AD, with EASI of 7 or lower and NRS for pruritus of 4 or lower varying between 78.6% and 92.3% and 72.2% and 88.2% for up to 5 years of treatment, respectively, while up to 70.5% of all patients prolonged the dosing interval to mostly 300 mg every 3 or 4 weeks. Mean EASI and NRS for pruritus were 2.7 (95% CI, 1.2-4.2) and 3.5 (95% CI, 2.7-4.3), respectively, after 5 years of treatment. Statistically significant differences between age groups were found over time for EASI and IGA; however, differences were rather small (week 52: EASI, 0.3-1.6; IGA, 0.12-0.26). No statistically significant differences between age groups were found for NRS for pruritus. Median thymus- and activation-related chemokine levels considerably decreased from 1751 pg/mL (95% CI, 1614-1900 pg/mL) to 390 pg/mL (95% CI, 368-413 pg/mL) after 6 months of treatment and remained low. Median eosinophil levels temporarily increased up to week 16, with a subsequently statistically significant decrease over time. In total, 306 patients (23.8%) discontinued dupilumab after a median (IQR) of 54.0 (29.0-110.00) weeks, with adverse events among 98 patients (7.6%) and ineffectiveness among 85 patients (6.6%) as the most frequently reported reasons. Forty-one patients (3.2%) restarted dupilumab, and most of these patients recaptured response. CONCLUSIONS AND RELEVANCE: In this cohort study with up to 5 years of follow-up, dupilumab maintained its clinical effectiveness, while two-thirds of patients tapered to a dosing interval of every 3 or 4 weeks. Treatment was discontinued in 23.8% of patients mainly due to adverse events and/or ineffectiveness.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Boesjes CM, Kamphuis E, de Graaf M, et al. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis. JAMA Dermatol. 2024. PMID: 39110432. doi:10.1001/jamadermatol.2024.2517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。